Dirk Kuyper, Alphatec Spine president and CEO, attributes the company’s success to a successful showing in the Japanese, Asian Pacific and Latin American markets in addition to the United States. During this quarter, the company received a boost from increasing sales of the PureGen product and the FDA clearance of the Solus anterior lumbar interbody fusion system.
The domestic market contributed $33.9 million to the company’s overall revenue, and its international revenue more than doubled since the first quarter of last year, representing $15.9 million. The company plans on focusing efforts on laser technology for the aging spine, minimally invasive procedures and biologics to gain a global share of the spine market, Mr. Kuyper said in the report.
Read the release on the financial results from Alphatec Spine.
Read Articles Related to Alphatec Spine:
Alphatec Spine Signs Agreement With Merlot OrthopediX for Spine Surgery Technology
Alphatec Holdings Names Former Johnson & Johnson Exec New CFO
Alphatec Spine Receives 510(k) Clearance for Solus System
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.